Information regarding the specific price of Kisqali 200mg is not available in the provided text. Drug pricing can vary based on factors such as geographic location, pharmacy, insurance coverage, and any applicable patient assistance programs.
How is Kisqali prescribed?
Kisqali (ribociclib) is an oral medication used in combination with an aromatase inhibitor as extended adjuvant treatment for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive breast cancer at high risk for recurrence [1]. It is also used in combination with endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer [1]. The recommended dose is 600 mg once daily for 21 consecutive days followed by 7 days off. Treatment cycles are 28 days [1].
What are the potential side effects of Kisqali?
Common side effects of Kisqali include low white blood cell counts, nausea, vomiting, diarrhea, hair loss, and fatigue [1]. Serious side effects can occur, including liver problems, abnormal heart rhythms (QT prolongation), and severe skin reactions [1].
When does Kisqali's patent expire?
Patent information for Kisqali is available through specialized services. DrugPatentWatch.com tracks patent expirations for pharmaceuticals [2]. For detailed patent expiry dates related to Kisqali, consulting resources like DrugPatentWatch.com would be necessary [2].
What are the treatment options for HR-positive, HER2-negative advanced breast cancer?
Treatment for HR-positive, HER2-negative advanced or metastatic breast cancer often involves a combination of endocrine therapy and targeted agents. CDK4/6 inhibitors, such as Kisqali, are a significant advancement in this area, used alongside endocrine-based therapies [1]. Other CDK4/6 inhibitors include abemaciclib and palbociclib [3].
What clinical trials support Kisqali's use?
Kisqali's efficacy has been demonstrated in clinical trials. MONALEESA-7 showed that Kisqali in combination with endocrine therapy significantly improved progression-free survival in premenopausal women with advanced breast cancer [1]. The PALLAS trial evaluated Kisqali as extended adjuvant treatment in early breast cancer, and results from the NATALEE trial demonstrated its benefit in reducing the risk of recurrence in early breast cancer [1].
How does Kisqali work?
Kisqali is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) [1]. These kinases play a role in cell cycle progression. By inhibiting CDK4/6, Kisqali helps to block the growth and proliferation of cancer cells [1].
Sources:
[1] https://www.kisqali.com/
[2] https://drugpatentwatch.com/
[3] https://www.cancer.gov/publications/drug-summaries/scientific-summary-palbociclib